Valuation: Curis, Inc.

Market Cap 3.51M 3.03M 2.85M 2.59M 4.87M 335M 4.95M 33.36M 13.04M 168M 13.17M 12.89M 558M P/E 2026 *
-0.06x
P/E 2027 * -0.12x
Enterprise Value 3.51M 3.03M 2.85M 2.59M 4.87M 335M 4.95M 33.36M 13.04M 168M 13.17M 12.89M 558M EV / Sales 2026 *
2x
EV / Sales 2027 * 0.38x
Free-Float
73.91%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Curis, Inc.

1 day-3.74%
1 week-55.22%
Current month-64.14%
1 month-63.86%
3 months-81.64%
6 months-92.17%
Current year-90.88%
1 week 1.54
Extreme 1.54
3.37
1 month 1.54
Extreme 1.54
5.6
Current year 1.54
Extreme 1.54
24.2
1 year 1.54
Extreme 1.54
39
3 years 1.54
Extreme 1.54
349.8
5 years 1.54
Extreme 1.54
3,616
10 years 1.54
Extreme 1.54
7,440
Manager TitleAgeSince
Chief Executive Officer 59 2018-09-23
Director of Finance/CFO 54 2022-08-04
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 2003-10-31
Chairman 84 2017-05-15
Director/Board Member 71 2010-06-02
Date Insider Type Main position Quantity % Market Cap.
7/7/26 Free

Chief Executive Officer

110,090 0.2824%
7/7/26 Free

Director

6,800 0.0174%
7/7/26 Free

Chairman

6,800 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-3.74%-55.22%-95.08%-99.32% 3.51M
-1.78%-1.68%+1.48%+17.26% 48.42B
+0.85%-0.70%+460.88%+581.30% 43.66B
-2.40%-0.23%+8.13%+80.67% 39.51B
-2.01%-0.85%+23.85%+9.97% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+126.36% 16.15B
+0.49%+0.92%+4.11%+26.37% 14.16B
-0.43%+4.70%+78.74%+38.66% 13.37B
Average -0.97%-5.56%+58.78%+93.27% 26.31B
Weighted average by Cap. -0.91%-0.12%+95.83%+140.26%

Financials

2026 *2027 *
Net sales 1.75M 1.51M 1.42M 1.29M 2.43M 167M 2.47M 16.64M 6.51M 83.8M 6.57M 6.43M 278M 9.25M 7.99M 7.51M 6.83M 12.84M 885M 13.05M 87.96M 34.39M 443M 34.73M 33.98M 1.47B
Net income -51.03M -44.07M -41.41M -37.66M -70.81M -4.88B -71.98M -485M -190M -2.44B -192M -187M -8.12B -46.12M -39.83M -37.43M -34.04M -64M -4.41B -65.05M -439M -171M -2.21B -173M -169M -7.34B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
26-08-14 US$1.800 -3.74% 470,549
26-08-13 US$1.870 +11.98% 2,292,957
26-08-12 US$1.670 -27.71% 1,147,013
26-08-11 US$2.310 -36.89% 600,781
26-08-10 US$3.660 -8.96% 72,953
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.800USD
Average target price
42.67USD
Spread / Average Target
+2,270.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRIS Stock